



AROA BIOSURGERY EXPECTS NO DISRUPTION FROM NEW AUCKLAND COVID-19 PREVENTION MEASURES

Auckland-based soft tissue regeneration company, Aroa Biosurgery Limited, (ASX:ARX, 'Aroa' or the 'Company') expects to continue to manufacture and ship its soft tissue regeneration products with no disruption, following the decision by the NZ Government to move Auckland City to 'Level 3' COVID-19 prevention measures from midday today NZ time (10.00am AEST).

The NZ Government has advised the Level 3 measures will be in place for an initial period of three days, pending an assessment of the degree of possible community transmission of COVID-19, following the discovery of four cases in Auckland yesterday.

Aroa is categorised as an "essential business" as it manufactures and sells medical devices. The Company continued to operate effectively during March and April this year, under more arduous and restrictive lockdown criteria (Level 4).

The Company is well equipped to continue manufacturing and shipping to export markets, with nil or minimal disruption to either in-bound or out-bound supply chains.

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

Contacts

Investor

Simon Hinsley

Investor Relations

shinsley@aroabio.com

+ 61 401 809 653

Media

Australia

Matthew Wright

matt@nwrcommunications.com.au

+61 451 896 420

New Zealand

Piet De Jong

piet.dejong@baldwinboyle.com

+64 21 812 766

About Aroa Biosurgery:

Aroa Biosurgery is a soft-tissue regeneration company that develops, manufactures, sells and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Committed to 'unlocking regenerative healing for everybody', its products are developed from the Company's proprietary Endoform® technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. Clinically proven with peer reviewed publications, Aroa's products have been used in more than four million procedures to date, with distribution into its key market of the United States by Appulse and Tela Bio.

Founded in 2008, Aroa is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX:ARX). www.aroabio.com/